查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1435150

抗惊厥药物市场：依药物类型、适应症划分 - 2024-2030 年全球预测

Anticonvulsants Market by Drug types (AMPA, Barbiturate, Benzodiazepine), Indication (Anxiety, Bipolar Disorder, Borderline Personality Disorder) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年抗惊厥药物市场规模为120.3亿美元，预计2024年将达130.7亿美元，2030年将达215.9亿美元，复合年增长率为8.71%。

全球抗惊厥药物市场

主要市场统计
基准年[2023] 120.3亿美元
预测年份 [2024] 130.7亿美元
预测年份 [2030] 215.9亿美元
复合年增长率（%） 8.71%
抗惊厥药市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估抗惊厥药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗惊厥药市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-抗惊厥药物市场规模及预测是多少？

2-抗惊厥药市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3-抗惊厥药物市场的技术趋势和法律规范是什么？

4-抗惊厥药物市场主要供应商的市场占有率是多少？

5-进入抗惊厥药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 年轻人和老年人的癫痫盛行率增加
      • 政府加大力度支持癫痫意识
      • 扩大在非癫痫疾病治疗的应用
    • 抑制因素
      • 疼痛管理替代方案的可用性
    • 机会
      • 抗惊厥药物的监管核准增加
      • 新一代抗癫痫药物的出现
    • 任务
      • 供不应求及二代药专利到期
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章依药物类型分類的抗惊厥药物市场

  • 安帕
  • 巴比妥类
  • 苯二氮平类
  • 氨基甲酸酯类抗惊厥药
  • 碳酸酐酶抑制剂
  • 二苯并氮卓
  • 三嗪

第七章 抗惊厥药物市场适应症

  • 焦虑
  • 躁郁症
  • 边缘性人格障碍
  • 癫痫
  • 纤维肌痛
  • 偏头痛
  • 神经性疼痛

第八章美洲抗惊厥药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区抗惊厥药市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲抗惊厥药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：按主要企业划分
  • 主要企业竞争情境分析

第12章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • Astrazeneca PLC
    • Bausch Health Companies Inc.
    • Biocon Limited
    • Cadila Pharmaceuticals Limited
    • Cipla, Inc.
    • Dr. Reddy's Laboratories Limited
    • Eisai Co., Ltd.
    • GlaxoSmithKline PLC
    • Glenmark Pharmaceuticals Ltd.
    • Jazz Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Lifecare Neuro Products Limited
    • Lundbeck A/S
    • Mankind Pharma Ltd.
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Wockhardt Limited
  • 主要产品系列

第十三章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-ED54C46E805C

[192 Pages Report] The Anticonvulsants Market size was estimated at USD 12.03 billion in 2023 and expected to reach USD 13.07 billion in 2024, at a CAGR 8.71% to reach USD 21.59 billion by 2030.

Global Anticonvulsants Market

KEY MARKET STATISTICS
Base Year [2023] USD 12.03 billion
Estimated Year [2024] USD 13.07 billion
Forecast Year [2030] USD 21.59 billion
CAGR (%) 8.71%
Anticonvulsants Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anticonvulsants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anticonvulsants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug types
    • AMPA
    • Barbiturate
    • Benzodiazepine
    • Carbamate Anticonvulsants
    • Carbonic Anhydrase Inhibitor
    • Dibenzazepine
    • Triazine
  • Indication
    • Anxiety
    • Bipolar Disorder
    • Borderline Personality Disorder
    • Epilepsy
    • Fibromyalgia
    • Migraine
    • Neuropathic Pain
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Anticonvulsants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anticonvulsants Market?

3. What are the technology trends and regulatory frameworks in the Anticonvulsants Market?

4. What is the market share of the leading vendors in the Anticonvulsants Market?

5. Which modes and strategic moves are suitable for entering the Anticonvulsants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Anticonvulsants Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of epilepsy among young and senior population
      • 5.1.1.2. Rising government initiatives supporting epilepsy awareness
      • 5.1.1.3. Expanding use in treating nonepileptic conditions
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of substitutes options for pain management
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
      • 5.1.3.2. Emergence of new-generation antiepileptic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Anticonvulsants Market, by Drug types

  • 6.1. Introduction
  • 6.2. AMPA
  • 6.3. Barbiturate
  • 6.4. Benzodiazepine
  • 6.5. Carbamate Anticonvulsants
  • 6.6. Carbonic Anhydrase Inhibitor
  • 6.7. Dibenzazepine
  • 6.8. Triazine

7. Anticonvulsants Market, by Indication

  • 7.1. Introduction
  • 7.2. Anxiety
  • 7.3. Bipolar Disorder
  • 7.4. Borderline Personality Disorder
  • 7.5. Epilepsy
  • 7.6. Fibromyalgia
  • 7.7. Migraine
  • 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anticonvulsants Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anticonvulsants Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Astrazeneca PLC
    • 12.1.3. Bausch Health Companies Inc.
    • 12.1.4. Biocon Limited
    • 12.1.5. Cadila Pharmaceuticals Limited
    • 12.1.6. Cipla, Inc.
    • 12.1.7. Dr. Reddy's Laboratories Limited
    • 12.1.8. Eisai Co., Ltd.
    • 12.1.9. GlaxoSmithKline PLC
    • 12.1.10. Glenmark Pharmaceuticals Ltd.
    • 12.1.11. Jazz Pharmaceuticals, Inc.
    • 12.1.12. Johnson & Johnson Services, Inc.
    • 12.1.13. Lifecare Neuro Products Limited
    • 12.1.14. Lundbeck A/S
    • 12.1.15. Mankind Pharma Ltd.
    • 12.1.16. Merck KGaA
    • 12.1.17. Novartis AG
    • 12.1.18. Novo Nordisk A/S
    • 12.1.19. Otsuka Pharmaceutical Co., Ltd.
    • 12.1.20. Pfizer Inc.
    • 12.1.21. Sanofi S.A.
    • 12.1.22. Sunovion Pharmaceuticals Inc.
    • 12.1.23. Takeda Pharmaceutical Company Limited
    • 12.1.24. Teva Pharmaceutical Industries Ltd.
    • 12.1.25. Wockhardt Limited
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTICONVULSANTS MARKET DYNAMICS
  • FIGURE 7. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
  • FIGURE 8. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 6. ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 41. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. INDIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 45. INDONESIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. JAPAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 49. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 51. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 53. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 55. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. TAIWAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 59. THAILAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. VIETNAM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. VIETNAM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 66. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. EGYPT ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. EGYPT ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 70. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ISRAEL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 76. ISRAEL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 78. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 80. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 82. NIGERIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NORWAY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 84. NORWAY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. POLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. POLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 90. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 92. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 96. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 100. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. TURKEY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 102. TURKEY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 108. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 109. ANTICONVULSANTS MARKET LICENSE & PRICING